Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGB101
- Development stage
- Phase 3
- Lead developer
- AgeneBio
- Modality
- Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
AGB101 is a proprietary, once-daily, low-dose extended-release oral formulation of levetiracetam developed by AgeneBio. It is being investigated primarily for the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's disease and to slow progression to Alzheimer's dementia. Unlike standard doses used in epilepsy, AGB101 uses approximately one-twelfth to one-fifteenth the typical anti-epileptic dose. Its mechanism targets hippocampal hyperactivity—a hallmark of early Alzheimer’s pathology—by modulating synaptic vesicle protein 2A (SV2A), aiming to restore brain network function and improve memory performance. Clinical trials have shown that in non-carriers of the ApoE-4 allele with MCI due to AD, AGB101 significantly reduced clinical decline and atrophy in key brain regions compared with placebo[1][6][7]. It is also under investigation for psychosis in Parkinson's disease and other neurocognitive disorders.
- Brand names
- AGB101AGB-101AGB 101
- Other names
- levetiracetam extended-release low-doseproprietary extended-release formulation of levetiracetam
02
Targets
SV2A (Synaptic vesicle glycoprotein 2A)
Beyond the preview
Go deeper on AGB101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGB101.